UBITUS
15.5.2024 11:34:35 CEST | Business Wire | Press release
Ubitus K.K. (hereinafter Ubitus), a leading cloud gaming technology provider, is thrilled to announce its participation in Viva Technology 2024, Europe’s biggest startup and tech event, taking place from May 22nd to May 25th at Paris Expo Porte de Versailles. Visitors can explore Ubitus' innovative solutions at Booth D38 in the TTA Pavilion, Hall 1, where you can express your creativity through Ubitus’ AI solutions.
Innovative Demonstrations at the Ubitus Booth
Ubitus is excited to showcase its AI technologies that increase creativity and productivity for everyone, including the debut of Ubi-chan in French and UbiArt, its visual art AI generative tool. Ubi-chan, Ubitus' AI V-tuber, will engage with attendees, providing an interactive experience that highlights the capabilities of AI in entertainment. Additionally, Ubitus will unveil UbiArt at the event, featuring unique “local style models” like the Taiwan Night Market, demonstrating the versatile applications of its technology in creating culturally rich digital art.
Keynote Speeches by CEO Wesley Kuo
Cloud vs Console: The Future of Gaming Platforms
Highlighting Ubitus' involvement, CEO Wesley Kuo will take the stage as an official speaker at VivaTech. Wesley Kuo is scheduled to present on "Cloud vs Console: The Future of Gaming Platforms" on May 23, from 9:45 AM to 10:30 AM on Stage 2. His speech session with Michael Fan, partner of Galaxy Interactive, and Joe Tidy, Cyber Correspondent of BBC News will address crucial topics in the gaming industry, discussing the transformative potential of cloud technology over traditional console platforms, impacts on market dynamics, the benefits of subscription-based models, and the implications for data privacy and game diversity. For more details on the session, please visit: https://vivatechnology.com/sessions/4a3a33b1-f2f0-ee11-aaf0-000d3a2b945f.
Introduction to Ubitus' AI Solutions
In addition, Wesley Kuo will deliver a second presentation on the main stage in the TTA Pavilion(Booth D38) at 2 PM on the same day, focusing on Ubitus' AI-driven initiatives.
Ubitus' participation in VivaTech 2024 showcases its commitment to innovation and its role in shaping the future of digital entertainment and AI applications. By introducing AI solutions like Ubi-chan, who will engage visitors in French, and UbiArt, which captures the essence of local cultures, showcasing the vibrant Taiwanese food culture, Ubitus is set to make a significant impact at this global tech event.
Join us at Viva Technology 2024 to experience the future of technology with Ubitus' innovative solutions. We look forward to welcoming you to our booth and sharing our vision for a connected world. For more information, please visit Ubitus K.K. website.
About Ubitus K.K.
Ubitus K.K. is a technology company that specializes in cloud solutions, GPU virtualization technology, and cloud streaming platform. Our focus is on delivering exceptional cloud and artificial intelligence services.
Leveraging the power of GPUs, Ubitus has developed multiple AI solutions, including UbiGPT (Taiwan LLM), Ubi Anchor (AI anchor), Ubi-chan (AI character), and UbiArt (image generation software). Ubitus is committed to delivering tailor-made solutions designed to meet the diverse requirements of customers in various industries. Our goal is to seamlessly incorporate a range of AI applications into distinctive situations, ensuring a customized approach for each use case.
Ubitus’ cloud gaming solution enables users to enjoy AAA gaming experiences across devices with just an internet connection. Through our comprehensive Game Development Kit (GDK), we offer patented technology for rapid deployment, catering towards international clients that are interested in cloud gaming, including console gaming platforms, telecom operators, and game developers.
For Metaverse solutions, Ubitus possesses extensive global cloud deployment experience via GameCloud® technology offerings. Ubitus is able to stream interactive media content for platform operators and digital content developers on multi-devices, which offers users an immersive experience that accelerates metaverse popularization.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515534843/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom